Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath

Completed

• Conditions: Parkinson's Disease; Parkinsonism
• Interventions: Other: collection of exhaled breath

• Registration Number: NCT01246336
• Lead Sponsor: Rambam Health Care Campus

Brief Summary

Parkinson's disease is diagnosed clinically, because biomarkers that may help in diagnosis and differential diagnosis are not yet available. Exhaled breath testing may yield a "breath-print" that can be used to distinguish healthy and diseased states.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-08
• Study First Submitted: 2010-11-21
• Study First Submitted QC: 2010-11-22
• Study First Posted: 2010-11-23
• Primary Completion: 2012-01
• Study Completion: 2012-01
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-30
• Last Update Posted: 2017-10-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

• Patients with Parkinsonism

Exclusion Criteria

• Severe dementia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with parkinsonism	collection of exhaled breath	Patients suffering from Parkinson's disease or parkinsonism
Healthy controls	collection of exhaled breath	Patients not suffering from Parkinson's disease or any other neurological disorder

Primary Outcome Measures

Name	Time	Method
Nanosensory detection	immediate	analyze combinations of nanomaterial-based sensors (organically functionalized carbon nanotubes and gold nanoparticles)